# Mkey Ventures

Mkey Venture Capital

### We are the



Use a scrol

## to unlock potential

# And our track record is our proof






















































#### Valery Vavilov

Co-founder and CEO at Bitfury Group

- Masters in Computer Science, MBA at Stanford University of Business
- investments like, Emercoin, Final Frontier, Rootstock, Abra and more
- One of the World's TOP 15 blockchain gurus

#### Marat Kichikov

Co-founder of Bitfury and Managing Partner of Bitfury Capital

- Bachelor ir law, Bachelor in BA, Masters inInternational Business Administration
- 20 + Angel investments, including Lokalise, HUT8,
  F3, Turing, Carta, LifeArk and more
- 10 + investments as Bitfury Capital GP, including Abra, Emercoin, BitPesa, BitGo, Longenesis and more
- Mentor in accelerators like Plug and Play, F50, different hackatons, etc.

#### Nikolay Oreshkin

Managing partner of Elysium Venture Capital

- MS in Devices, systems and products for medical purposes at Technical University Munich,
   Entrepreneurial studies at Stanford University of Business
- 20 + investments, including Telegram, GoodWork, Hub, EOS, Capture Technologies and more
- Associated partner of F50, Vice President of GVA Capital

#### EdTech

E-commerce

Tech

SaaS

# We feel the best in

Abou

Blockchain

Med-tech

Fintech

Big Data

# And we are looking for

- Companies that seek for Pre-seed, seed, series A investments
- Located in: US, EU, CIS, ASIA

- Has Little time to market
- And present Innovation, disruptive technologies and added value

## Use a scr

# And LPs that

- Are ready to involve
- Can bring added value
- And have passion for the dynamic world of start-ups



# Whats our plan?

ur plaı

Mkey Ventures Fund I

\$15 million

Mkey Ventures Fund II


\$25 million

Mkey Ventures Fund III

\$50 million



# Timeline



# Key Terms

Term: 10 years

GP Capital Commitment: 10%

Investment Period: 5 years

Carried Interest: 20%

Distributions: LPs before GPs

Management Fee: 2% reduced by 20% p.a. while on hold

Number of investments: 20–35

# Portfolio Composition

# Portfolio Composition

for all three funds together

Seed 42%

Pre-seed 33%

Series A 25%





# Use a scrol

# Key Contacts

#### Valery Vavilov

v.vavilov@mkey.vc +44 (755) 888-1888

#### Marat Kichikov

m.kickihov@mkey.vc +1 (650) 889-0261

#### Nikolay Oreshkin

n.oreshkin@mkey.vc +1 (415) 767-6111



### Legal Notices

This presentation is intended for limited circulation and is provided to the recipient on a confidential basis so that they may consider an investment in MKey Ventures (the "Fund"). The recipient expressly acknowledges and agrees that they will hold this information, this document, and all related documents and disclosures in the strictest confidence. This document is not intended for public use or distribution, and dissemination, publication, distribution, disclosure, copying or use of the information, documents, or disclosures contained herein is expressly prohibited.

These materials do not purport to be all-inclusive or to contain all the information that a prospective investor may desire in investigating the Fund. These materials are merely for preliminary discussion only and may not be relied upon for making any investment decision with respect to the Fund. Rather, prospective investors should rely upon the Fund's definitive agreement of limited partnership and their own independent investigation of the Fund. In the event that any of the terms of this presentation are inconsistent with or contrary to the agreement of limited partnership, such agreement shall control.

The limited partner interests in the Fund have not been registered under the United States Securities Act of 1933, as amended, or under any applicable state securities laws, nor have such limited partner interests been approved or disapproved by the United States Securities and Exchange Commission (the "SEC") or the securities regulatory authority of any state or other jurisdiction. Neither the SEC nor any commissioner of any such state authority or other jurisdiction has passed upon the accuracy or adequacy of this presentation, and any representation to the contrary is unlawful.

This presentation may contain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. Because such forward-looking statements involve risks and uncertainties, actual results of the Fund may differ materially from any expectations, projections or predictions made or implicated in such forward-looking statements. Prospective investors are therefore cautioned not to place undue reliance on such forward-looking statements.

This presentation speaks as of the date hereof and neither the general partner of the Fund nor any affiliate or representative thereof assumes any obligation to provide any recipient of this presentation with subsequent revisions or updates to any historical or forward-looking information contained in this presentation to reflect the occurrence of events and/or changes in circumstances after the date hereof. This presentation does not constitute an offer to sell or a solicitation of interest to purchase any securities or investment advisory services in any state or in any other jurisdiction in which such offer or solicitation is not authorized.

An investment in the Fund is speculative and involves a high degree of risk. Opportunities for withdrawal and transferability of interests are restricted, so investors may not have access to capital when it is needed. There is no secondary market for the interests, and none is expected to develop. An investor should not make an investment unless it is prepared to lose all or a substantial portion of its investment. The fees and expenses charged in connection with this investment may be higher than the fees and expenses of other investment alternatives and may offset profits. Nothing presented herein is intended to constitute investment advice, and no investment decision should be made based on any information provided herein. Past performance is not indicative of future results.